论文部分内容阅读
目的探讨独活寄生汤联合唑来膦酸治疗绝经后肝肾亏虚型骨质疏松症(PO)的疗效。方法选取2009年2月-2012年12月收治的210例绝经后肝肾亏虚型PO患者,且所有患者均愿意接受研究。采用随机对照试验法,将患者分为A、B、C 3组各70例。A组采用独活寄生汤联合唑来膦酸治疗;B组采用唑来膦酸治疗;C组采用独活寄生汤治疗。观察3组患者治疗前后骨密度、骨源性碱性磷酸酶(NBAP)、骨钙素(BGP)、雌二醇(E2)变化,疗效及不良反应。结果骨密度、NBAP、BGP、E2各项指标,治疗前3组患者比较差异无统计学意义(P>0.05);治疗后A组各项指标明显优于B组、C组(P<0.05);B组与C组对比,差异无统计学意义(P>0.05);治疗后A组总有效率为97.14%,与B组、C组对比,差异有统计学意义(P<0.05)。3组均未见严重不良反应。结论独活寄生汤联合唑来膦酸治疗绝经后肝肾亏虚型PO疗效显著,可有效提高患者骨密度、BGP、E2含量,降低骨源性碱性磷酸酶含量,缓解骨质疏松,且无严重不良反应发生,值得临床推广。
Objective To investigate the curative effect of Doxue parasitic soup combined with Zoledronic acid in the treatment of postmenopausal liver and kidney deficiency type osteoporosis (PO). Methods A total of 210 PO patients with postmenopausal liver and kidney deficiency type were enrolled from February 2009 to December 2012, and all the patients were eligible for the study. Patients were divided into A, B and C groups of 70 patients by randomized controlled trial. Group A was treated with zoledronic acid combined with zoledronic acid; group B was treated with zoledronic acid; group C was treated with indoxacin alone. The bone mineral density (BMD), bone mineral alkaline phosphatase (NBAP), BGP and estradiol (E2) in the three groups were observed before and after treatment. The curative effects and adverse reactions were observed. Results There was no significant difference in BMD, NBAP, BGP and E2 between the three groups before treatment (P> 0.05). After treatment, the indexes in group A were significantly better than those in group B and group C (P <0.05) ; There was no significant difference between group B and group C (P> 0.05). After treatment, the total effective rate of group A was 97.14%. There was significant difference between group B and group C (P <0.05). No serious adverse reactions were observed in all three groups. Conclusion Dofu parasitic soup combined with zoledronic acid treatment of postmenopausal syndrome of liver and kidney deficiency type of PO significant effect, which can effectively increase bone mineral density, BGP, E2 content, reduce bone alkaline phosphatase, and alleviate osteoporosis, and no Serious adverse reactions occur, it is worth clinical promotion.